uniQure (QURE) Expected to Announce Earnings on Wednesday

uniQure (NASDAQ:QURE) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect uniQure to post earnings of ($0.9152) per share and revenue of $6.17 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

uniQure Stock Performance

NASDAQ QURE opened at $24.83 on Monday. The stock has a fifty day simple moving average of $34.55 and a 200-day simple moving average of $29.67. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.72 billion, a PE ratio of -6.19 and a beta of 1.14. uniQure has a twelve month low of $8.73 and a twelve month high of $68.62.

Wall Street Analysts Forecast Growth

Several brokerages have commented on QURE. UBS Group started coverage on shares of uniQure in a research report on Thursday, October 15th. They issued a “buy” rating and a $48.00 price target for the company. Royal Bank Of Canada cut their price objective on uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, October 2nd. HC Wainwright reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, September 29th. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a report on Wednesday, July 29th. Finally, The Goldman Sachs Group lowered their target price on uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.25.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.